^
    Back
    Association details:
    Biomarker:EGFR L746_T750del
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    N Engl J Med
    Title:

    Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

    Excerpt:
    Heterozygous mutations were observed in eight of nine patients, all of which were clustered within the tyrosine kinase domain of EGFR (Table 2 and Figure 2)....Both had in-frame deletions in the kinase domain that were identical to those found in the patients with a response to gefitinib — namely, delL747–P753insS and delE746–A750 (Table 2).
    DOI:
    10.1056/NEJMoa040938
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Intern Med
    Title:

    The Long-term Survival of a Patient with Adenosquamous Lung Carcinoma Harboring EGFR-activating Mutations Who was Treated with Gefitinib

    Excerpt:
    A 56-year-old woman...after a transbronchoscopic examination underwent left upper lobectomy, which revealed a pathological diagnosis of adenosquamous carcinoma...The epidermal growth factor receptor (EGFR) exon 19 delE746-A750 mutation was detected...Treatment with the EGFR tyrosine kinase inhibitor, gefitinib, resulted in a long-term tumor response lasting three years.
    DOI:
    10.2169/internalmedicine.51.7428